Aggressive B-Cell Lymphoma
Aggressive B-Cell Lymphoma
The latest news, research, and perspectives in aggressive B-cell lymphoma. These fast-growing non-Hodgkin lymphomas, including diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma, arise at different stages of B-cell development.
Leah SherwoodAggressive B-Cell Lymphoma | December 5, 2022
A combination of rituximab, lenalidomide, and ibrutinib produced a high overall response rate in newly diagnosed DLBCL.
Read More
Leah SherwoodAggressive B-Cell Lymphoma | December 5, 2022
Ibrutinib treatment was associated with higher survival rates in patients with mantle cell lymphoma (MCL) and CNS relapse.
Leah SherwoodAggressive B-Cell Lymphoma | November 29, 2022
End of treatment high-dose methotrexate did not increase risk of CNS relapse compared with intercalated delivery.
Leah SherwoodAggressive B-Cell Lymphoma | November 23, 2022
The ​European Medicines Agency recommended Marketing Authorization of loncastuximab tesirine for relapsed/refractory DLBCL.
Leah SherwoodAggressive B-Cell Lymphoma | November 21, 2022
The FDA approved a priority review of the BLA for subcutaneous epcoritamab in relapsed/refractory large B-cell lymphoma.
Leah SherwoodAggressive B-Cell Lymphoma | October 27, 2022
Does the route of administration matter in preventing CNS relapse in agressive B-cell lymphomas?
Leah SherwoodAggressive B-Cell Lymphoma | October 25, 2022
The EC has granted marketing authorization to axicabtagene ciloleucel for the treatment of adult patients with DLBCL and ...
Leah SherwoodAggressive B-Cell Lymphoma | September 22, 2022
Elias Jabbour, MD, shares what he is most looking forward to at the 2022 SOHO Annual Meeting.
Kerri FitzgeraldAggressive B-Cell Lymphoma | September 13, 2022
The addition of brentuximab vedotin improved survival in Hodgkin lymphoma.
Kerri FitzgeraldAggressive B-Cell Lymphoma | September 13, 2022
Pola-R-CHP may be cost-effective for the treatment of DLBCL.
Kerri FitzgeraldPrint | September 13, 2022
Dr. Pro discusses the exciting advancements made in lymphoma and what still needs to be done to improve patient outcomes.
Cecilia BrownAggressive B-Cell Lymphoma | August 8, 2022
Ibrutinib combined with standard chemoimmunotherapy significantly prolonged progression-free survival in older patients.
Cecilia BrownAggressive B-Cell Lymphoma | August 8, 2022
A new model that makes use of a promising imaging biomarker can predict diffuse large B-cell lymphoma relapse and survival ...
Leah SherwoodAggressive B-Cell Lymphoma | August 4, 2022
Researchers have demonstrated the clinical importance of COVID-19 vaccination after anti-CD19 chimeric antigen receptor (CAR) ...
Cecilia BrownAggressive B-Cell Lymphoma | July 25, 2022
Axicabtagene ciloleucel, an autologous anti-CD19 CAR T-cell treatment, improved quality of life compared to standard of care ...
Leah SherwoodAggressive B-Cell Lymphoma | July 15, 2022
The European Medicines Agency validated a type II variation for the extension of the indication for lisocabtagene maraleucel ...
Leah SherwoodAggressive B-Cell Lymphoma | July 15, 2022
The U.S. Food and Drug Administration cleared an investigational new drug application for ACE1831, an anti-CD20 armed ...
Leah SherwoodAggressive B-Cell Lymphoma | July 6, 2022
In the study, 11 patients with relapsed/refractory diffuse LBCL were infused with anbal-cel.
Kerri FitzgeraldAggressive B-Cell Lymphoma | June 23, 2022
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use recommended the conditional approval ...
Kerri FitzgeraldAggressive B-Cell Lymphoma | June 23, 2022
The European Commission has approved the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel for the treatment of ...
Advertisement
Editorial Board

Advertisement